Antev Pharma is a biopharmaceutical company developing two therapeutic candidates: SkinJect, a transdermal patch for non-melanoma skin cancer, and Teverelix, a peptide-based treatment for advanced prostate cancer and recurrent urinary retention. The company is in early clinical development stages and has not yet commercialized any products or generated revenue; its business model depends on successful completion of Phase 2b clinical trials, FDA regulatory approval, development of manufacturing and supply chain capabilities, and establishment of sales and marketing infrastructure, either independently or through strategic partnerships with larger pharmaceutical companies. Antev anticipates continued operating losses until commercialization, requiring substantial additional financing to support ongoing development efforts.